Showing results (221-230 of 589) with videos related to
Sort By:
Pageof 59
Cancer Research|May 4, 2021
Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon ResponseHyeongjwa Choi, Juntae Kwon, Min Soon Cho, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeuticsMichael B Atkins, David Carbone, George Coukos, et al.Investigational New Drugs|January 28, 2021
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapyToni K Choueiri, Michael B Atkins, Tracy L Rose, et al.Journal for Immunotherapy of Cancer|July 15, 2020
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspectiveCasey Quinn, Louis P Garrison, Anja K Pownell, et al.Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.European Urology|September 17, 2020
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell CarcinomaSumanta K Pal, Bernard J Escudier, Michael B Atkins, et al.BJU International|March 17, 2010
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapyToni K Choueiri, Meredith M Regan, Jonathan E Rosenberg, et al.Cancer Research|April 19, 2005
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasionArnold H Zea, Paulo C Rodriguez, Michael B Atkins, et al.Developmental Cell|May 8, 2019
YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor CellsShannon M White, Maria Laura Avantaggiati, Ivan Nemazanyy, et al.Journal for Immunotherapy of Cancer|December 19, 2019
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infectionNeil J Shah, Ghassan Al-Shbool, Matthew Blackburn, et al.Pageof 59